Shopping Cart 0
Cart Subtotal
AED 0

Cholera Vaccine Market by Product (Dukoral, Shanchol, Vaxchora, Euvichol & Euvichol-Plus, and others) and End User (Hospitals & Clinics, Research & Academic Laboratories, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 19708

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 33012

Details

According to a new report published by Allied Market Research, titled, "Cholera Vaccine Market by Product and End User: Global Opportunity Analysis and Industry Forecast, 2018-2025," the global cholera vaccine market generated USD 65 million in 2017, and is projected to reach USD 207 million by 2025, growing at a CAGR of 15.6% from 2018 to 2025. The Dukoral segment accounted around half of the total market share in 2017.
 
Cholera is an acute, profusely watery diarrhea caused by Vibrio cholera and spreads through contamination of water and food. In addition, it is closely associated with poor sanitation and lack of clean drinking water. The number of global cholera disease cases accounts for around 35 million every year. Currently, the frequency of cholera epidemics has increased mainly in low- and middle-income countries. Cholera control is the main priority in cholera-endemic areas, which in turn increase the demand for the cholera vaccines.
 
The cholera vaccine market is expected to exhibit significant growth during the forecast period due to lack of proper sanitation & consumption of contaminated food and growth in awareness about cholera preventive care. In addition, development of novel approaches for new cholera vaccine further drive the market growth. However, risk of adverse effects and the time taken for the regulatory approval is projected to impede the market growth. On the contrary, high growth opportunities in untapped markets are expected to offer significant profitable opportunities for the market players in the near future.
 
Based on end user, the market is categorized into hospitals & clinics, research & academic laboratories, and others. The hospitals & clinics segment presently dominates the market, and is expected to remain dominant during the forecast period. This is attributed to the fact that hospitals and clinics are authorized to organize campaigns for cholera vaccination, as the number of cases for cholera diseases is rapidly growing in LMICs.
 
Asia-Pacific was the leading revenue contributor to the global cholera vaccine market in 2017, and is expected to remain dominant throughout the forecast period due to increase in the prevalence of cholera disease and rise in importance of immunization. However, North America is expected to grow at the highest CAGR during the study period. This is attributed to the launch of the first and only oral cholera vaccine, Vaxchora, in the USA. Furthermore, the number of travelers to the cholera-affected countries is increasing, which in turn increases the demand for immunization.
 
The report provides a comprehensive analysis of the key players operating in the global cholera vaccine market industry, namely Valneva SE, Emergent BioSolutions, Inc. (PaxVax, Inc.), Astellas Pharma, Inc., Sanofi (Shantha Biotechnics Private Limited), Eubiologics Co., Ltd., and Johnson & Johnson (Crucell), Celldex Therapeutics, Inc. The other players in the in the cholera vaccine market industry include Merck & Co., Inc., GlaxoSmithKline plc., and others.
 
Key Findings Of The Study
 
Based on product, the Vaxchora segment is expected to experience rapid growth in the market, and is projected to grow at a CAGR of 17.4% from 2018 to 2025.
 
Depending on end user, the pharmaceutical & biotechnology companies segment is expected to exhibit the highest CAGR during the forecast period.
 
U.S. generated the highest revenue in the global cholera vaccine market industry in 2017, accounting less than one-tenth of the global market in 2017.
 
North America is estimated to grow at a CAGR of 17.1% during the forecast period.
READ MORE

Table Of Content

Scope

CHAPTER 1: INTRODUCTION

 

1.1. Report description

1.2. Key benefits for stakeholders

1.3. Key market segments

 

1.3.1. List of key players profiled in the report

 

1.4. Research methodology

 

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools and models

 

CHAPTER 2: EXECUTIVE SUMMARY

 

2.1.1. CXO perspective

 

CHAPTER 3: MARKET OVERVIEW

 

3.1. Market definition and scope

3.2. Key findings

 

3.2.1. Top investment pockets

 

3.3. Top Player Positioning, 2017

3.4. Porters five forces analysis

3.5. Market dynamics

 

3.5.1. Drivers

 

3.5.1.1. Lack of proper sanitation and consumption of contaminated food

3.5.1.2. Rise in awareness about cholera preventive care

3.5.1.3. Development of novel approaches for new cholera vaccine

 

3.5.2. Restraints

 

3.5.2.1. Risk of adverse effects

3.5.2.2. The time taken for the regulatory approval

 

3.5.3. Opportunities

 

3.5.3.1. High growth opportunities in untapped markets

 

CHAPTER 4: CHOLERA VACCINE MARKET, BY PRODUCT

 

4.1. Overview

 

4.1.1. Market size and forecast

 

4.2. Dukoral

 

4.2.1. Key market trends and growth opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market analysis, by country

 

4.3. Shanchol

 

4.3.1. Key market trends and growth opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market analysis, by country

 

4.4. Vaxchora

 

4.4.1. Key market trends and growth opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market analysis, by country

 

4.5. Euvichol & Euvichol-Plus

 

4.5.1. Key market trends and growth opportunities

4.5.2. Market size and forecast, by region

4.5.3. Market analysis, by country

 

4.6. Others

 

4.6.1. Key market trends and growth opportunities

4.6.2. Market size and forecast, by region

4.6.3. Market analysis, by country

 

CHAPTER 5: CHOLERA VACCINE MARKET, BY END USER

 

5.1. Overview

 

5.1.1. Market size and forecast

 

5.2. Hospitals & Clinics

 

5.2.1. Market size and forecast, by region

5.2.2. Market analysis, by country

 

5.3. Research & Academic Laboratories

 

5.3.1. Market size and forecast, by region

5.3.2. Market analysis, by country

 

5.4. Others

 

5.4.1. Market size and forecast, by region

5.4.2. Market analysis, by country

 

CHAPTER 6: CHOLERA VACCINE MARKET, BY REGION

 

6.1. Overview

 

6.1.1. Market size and forecast

 

6.2. North America

 

6.2.1. Key market trends and opportunities

6.2.2. North America cholera vaccine market, by country

 

6.2.2.1. U.S. cholera vaccine market by product

6.2.2.2. U.S. cholera vaccine market by end user

6.2.2.3. Canada cholera vaccine market by product

6.2.2.4. Canada cholera vaccine market by end user

6.2.2.5. Mexico cholera vaccine market by product

6.2.2.6. Mexico cholera vaccine market by end user

 

6.2.3. North America cholera vaccine market, by product

6.2.4. North America cholera vaccine market, by end user

 

6.3. Europe

 

6.3.1. Key market trends and opportunities

6.3.2. Europe cholera vaccine market, by country

 

6.3.2.1. Germany cholera vaccine market by product

6.3.2.2. Germany cholera vaccine market by end user

6.3.2.3. France cholera vaccine market by product

6.3.2.4. France cholera vaccine market by end user

6.3.2.5. UK cholera vaccine market by product

6.3.2.6. UK cholera vaccine market by end user

6.3.2.7. Italy cholera vaccine market by product

6.3.2.8. Italy cholera vaccine market by end user

6.3.2.9. Sweden cholera vaccine market by product

6.3.2.10. Sweden cholera vaccine market by end user

6.3.2.11. Rest of Europe cholera vaccine market by product

6.3.2.12. Rest of Europe cholera vaccine market by end user

 

6.3.3. Europe cholera vaccine market, by product

6.3.4. Europe cholera vaccine market, by end user

 

6.4. Asia-Pacific

 

6.4.1. Key market trends and opportunities

6.4.2. Asia-Pacific cholera vaccine market, by country

 

6.4.2.1. Australia cholera vaccine market by product

6.4.2.2. Australia cholera vaccine market by end user

6.4.2.3. Japan cholera vaccine market by product

6.4.2.4. Japan cholera vaccine market by end user

6.4.2.5. India cholera vaccine market by product

6.4.2.6. India cholera vaccine market by end user

6.4.2.7. Vietnam cholera vaccine market by product

6.4.2.8. Vietnam cholera vaccine market by end user

6.4.2.9. Rest of Asia-Pacific cholera vaccine market by product

6.4.2.10. Rest of Asia-Pacific cholera vaccine market by end user

 

6.4.3. Asia-Pacific cholera vaccine market, by product

6.4.4. Asia-Pacific cholera vaccine market, by end user

 

6.5. LAMEA

 

6.5.1. Key market trends and opportunities

6.5.2. LAMEA cholera vaccine market, by country

 

6.5.2.1. Nigeria cholera vaccine market by product

6.5.2.2. Nigeria cholera vaccine market by end user

6.5.2.3. Malawi cholera vaccine market by product

6.5.2.4. Malawi cholera vaccine market by end user

6.5.2.5. Zambia cholera vaccine market by product

6.5.2.6. Zambia cholera vaccine market by end user

6.5.2.7. Rest of LAMEA cholera vaccine market by product

6.5.2.8. Rest of LAMEA cholera vaccine market by end user

 

6.5.3. LAMEA cholera vaccine market, by product

6.5.4. LAMEA cholera vaccine market, by end user

 

CHAPTER 7: COMPANY PROFILES

 

7.1. Astellas Pharma, Inc.

 

7.1.1. Company overview

7.1.2. Company snapshot

7.1.3. Business performance

 

7.2. Celldex Therapeutics, Inc.

 

7.2.1. Company overview

7.2.2. Company snapshot

7.2.3. Business performance

7.2.4. Key strategic moves and developments

 

7.3. Emergent BioSolutions, Inc. (PaxVax, Inc.)

 

7.3.1. Company overview

7.3.2. Company snapshot

7.3.3. Operating business segments

7.3.4. Business performance

 

7.4. Eubiologics Co., Ltd.

 

7.4.1. Company overview

7.4.2. Company snapshot

 

7.5. Johnson & Johnson (Crucell)

 

7.5.1. Company overview

7.5.2. Company snapshot

7.5.3. Operating business segments

7.5.4. Business performance

 

7.6. Sanofi (Shantha Biotechnics Private Limited)

 

7.6.1. Company overview

7.6.2. Company snapshot

7.6.3. Operating business segments

7.6.4. Business performance


List Of Figure

LIST OF FIGURES

 

FIGURE 01. CHOLERA VACCINE MARKET SEGMENTATION

FIGURE 02. TOP INVESTMENT POCKETS IN THE GLOBAL CHOLERA VACCINE MARKET

FIGURE 03. GLOBAL POWERED SURGICAL INSTRUMENT TOP PLAYER POSITIONING, 2017

FIGURE 04. MODERATE BARGAINING POWER OF BUYERS

FIGURE 05. HIGH BARGAINING POWER OF SUPPLIERS

FIGURE 06. LOW THREAT OF NEW ENTRANTS

FIGURE 07. MODERATE THREAT OF SUBSTITUTION

FIGURE 08. HIGH COMPETITIVE RIVALRY

FIGURE 09. DRIVERS, RESTRAINTS, AND OPPORTUNITIES: GLOBAL CHOLERA VACCINE MARKET

FIGURE 10. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR DUKORAL, BY COUNTRY, 2017 & 2025 (USD MILLION)

FIGURE 11. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR SHANCHOL, BY COUNTRY, 2017 & 2025 (USD MILLION)

FIGURE 12. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR VAXCHORA, BY COUNTRY, 2017 & 2025 (USD MILLION)

FIGURE 13. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR EUVICHOL AND EUVICHOL-PLUS, BY COUNTRY, 2017 & 2025 (USD MILLION)

FIGURE 14. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR OTHER PRODUCTES, BY COUNTRY, 2017 & 2025 (USD MILLION)

FIGURE 15. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2017 & 2025 (USD MILLION)

FIGURE 16. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY COUNTRY, 2017 & 2025 (USD MILLION)

FIGURE 17. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR OTHER END USERS, BY COUNTRY, 2017 & 2025 (USD MILLION)

FIGURE 18. ASTELLAS PHARMA: NET SALES, 20162018 (USD MILLION)

FIGURE 19. ASTELLAS PHARMA: REVENUE SHARE BY PRODUCT SEGMENT, 2018 (%)

FIGURE 20. ASTELLAS PHARMA: REVENUE SHARE BY GEOGRAPHY, 2018 (%)

FIGURE 21. CELLDEX: NET SALES, 20152017 (USD MILLION)

FIGURE 22. EMERGENT BIOSOLUTIONS: NET SALES, 20152017 (USD MILLION)

FIGURE 23. EMERGENT BIOSOLUTIONS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 24. J&J: NET SALES, 20152017 (USD MILLION)

FIGURE 25. J&J: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 26. J&J: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 27. SANOFI: NET SALES, 20152017 (USD MILLION)

FIGURE 28. SANOFI: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 29. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2017 (%)


List Of Table

LIST OF TABLES

 

TABLE 01. GLOBAL CHOLERA VACCINE MARKET, BY PRODUCT, 20172025 (USD MILLION)

TABLE 02. CHOLERA VACCINE MARKET FOR DUKORAL, BY REGION, 20172025 (USD MILLION)

TABLE 03. CHOLERA VACCINE MARKET FOR SHANCHOL, BY REGION, 20172025 (USD MILLION)

TABLE 04. CHOLERA VACCINE MARKET FOR VAXCHORA, BY REGION, 20172025 (USD MILLION)

TABLE 05. CHOLERA VACCINE MARKET FOR EUVICHOL AND EUVICHOL-PLUS BY REGION, 20172025 (USD MILLION)

TABLE 06. CHOLERA VACCINE MARKET FOR OTHER PRODUCTES BY REGION, 20172025 (USD MILLION)

TABLE 07. GLOBAL CHOLERA VACCINE MARKET, BY END USER, 20172025 (USD MILLION)

TABLE 08. CHOLERA VACCINE MARKET FOR HOSPITALS & CLINICS, BY REGION, 20172025 (USD MILLION)

TABLE 09. CHOLERA VACCINE MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY REGION, 20172025 (USD MILLION)

TABLE 10. CHOLERA VACCINE MARKET FOR OTHER END USERS, BY REGION, 20172025 (USD MILLION)

TABLE 11. GLOBAL CHOLERA VACCINE MARKET REVENUE, BY REGION, 20172025 (USD MILLION)

TABLE 12. NORTH AMERICA CHOLERA VACCINE MARKET, BY COUNTRY, 2017-2025 (USD MILLION)

TABLE 13. U.S. CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 14. U.S. CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 15. CANADA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 16. CANADA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 17. MEXICO CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 18. MEXICO CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 19. NORTH AMERICA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 20. NORTH AMERICA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 21. EUROPE CHOLERA VACCINE MARKET, BY COUNTRY, 2017-2025 (USD MILLION)

TABLE 22. GERMANY CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 23. GERMANY CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 24. FRANCE CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 25. FRANCE CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 26. UK CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 27. UK CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 28. ITALY CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 29. ITALY CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 30. SWEDEN CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 31. SWEDEN CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 32. REST OF EUROPE CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 33. REST OF EUROPE CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 34. EUROPE CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 35. EUROPE CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 36. ASIA-PACIFIC CHOLERA VACCINE MARKET, BY COUNTRY, 2017-2025 (USD MILLION)

TABLE 37. AUSTRALIA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 38. AUSTRALIA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 39. JAPAN CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 40. JAPAN CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 41. INDIA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 42. INDIA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 43. VIETNAM CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 44. VIETNAM CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 45. REST OF ASIA-PACIFIC CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 46. REST OF ASIA-PACIFIC CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 47. ASIA-PACIFIC CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 48. ASIA-PACIFIC CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 49. LAMEA CHOLERA VACCINE MARKET, BY COUNTRY, 2017-2025 (USD MILLION)

TABLE 50. NIGERIA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 51. NIGERIA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 52. MALAWI CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 53. MALAWI CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 54. ZAMBIA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 55. ZAMBIA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 56. REST OF LAMEA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 57. REST OF LAMEA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 58. LAMEA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 59. LAMEA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 60. ASTELLAS PHARMA: COMPANY SNAPSHOT

TABLE 61. CELLDEX: COMPANY SNAPSHOT

TABLE 62. EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT

TABLE 63. EMERGENT BIOSOLUTIONS: OPERATING SEGMENTS

TABLE 64. EUBIOLOGICS: COMPANY SNAPSHOT

TABLE 65. J&J: COMPANY SNAPSHOT

TABLE 66. J&J: OPERATING SEGMENTS

TABLE 67. SANOFI: COMPANY SNAPSHOT

TABLE 68. SANOFI: OPERATING SEGMENTS

Licence Rights

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

According to a new report published by Allied Market Research, titled, "Cholera Vaccine Market by Product and End User: Global Opportunity Analysis and Industry Forecast, 2018-2025," the global cholera vaccine market generated USD 65 million in 2017, and is projected to reach USD 207 million by 2025, growing at a CAGR of 15.6% from 2018 to 2025. The Dukoral segment accounted around half of the total market share in 2017.
 
Cholera is an acute, profusely watery diarrhea caused by Vibrio cholera and spreads through contamination of water and food. In addition, it is closely associated with poor sanitation and lack of clean drinking water. The number of global cholera disease cases accounts for around 35 million every year. Currently, the frequency of cholera epidemics has increased mainly in low- and middle-income countries. Cholera control is the main priority in cholera-endemic areas, which in turn increase the demand for the cholera vaccines.
 
The cholera vaccine market is expected to exhibit significant growth during the forecast period due to lack of proper sanitation & consumption of contaminated food and growth in awareness about cholera preventive care. In addition, development of novel approaches for new cholera vaccine further drive the market growth. However, risk of adverse effects and the time taken for the regulatory approval is projected to impede the market growth. On the contrary, high growth opportunities in untapped markets are expected to offer significant profitable opportunities for the market players in the near future.
 
Based on end user, the market is categorized into hospitals & clinics, research & academic laboratories, and others. The hospitals & clinics segment presently dominates the market, and is expected to remain dominant during the forecast period. This is attributed to the fact that hospitals and clinics are authorized to organize campaigns for cholera vaccination, as the number of cases for cholera diseases is rapidly growing in LMICs.
 
Asia-Pacific was the leading revenue contributor to the global cholera vaccine market in 2017, and is expected to remain dominant throughout the forecast period due to increase in the prevalence of cholera disease and rise in importance of immunization. However, North America is expected to grow at the highest CAGR during the study period. This is attributed to the launch of the first and only oral cholera vaccine, Vaxchora, in the USA. Furthermore, the number of travelers to the cholera-affected countries is increasing, which in turn increases the demand for immunization.
 
The report provides a comprehensive analysis of the key players operating in the global cholera vaccine market industry, namely Valneva SE, Emergent BioSolutions, Inc. (PaxVax, Inc.), Astellas Pharma, Inc., Sanofi (Shantha Biotechnics Private Limited), Eubiologics Co., Ltd., and Johnson & Johnson (Crucell), Celldex Therapeutics, Inc. The other players in the in the cholera vaccine market industry include Merck & Co., Inc., GlaxoSmithKline plc., and others.
 
Key Findings Of The Study
 
Based on product, the Vaxchora segment is expected to experience rapid growth in the market, and is projected to grow at a CAGR of 17.4% from 2018 to 2025.
 
Depending on end user, the pharmaceutical & biotechnology companies segment is expected to exhibit the highest CAGR during the forecast period.
 
U.S. generated the highest revenue in the global cholera vaccine market industry in 2017, accounting less than one-tenth of the global market in 2017.
 
North America is estimated to grow at a CAGR of 17.1% during the forecast period.
READ MORE

Scope

CHAPTER 1: INTRODUCTION

 

1.1. Report description

1.2. Key benefits for stakeholders

1.3. Key market segments

 

1.3.1. List of key players profiled in the report

 

1.4. Research methodology

 

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools and models

 

CHAPTER 2: EXECUTIVE SUMMARY

 

2.1.1. CXO perspective

 

CHAPTER 3: MARKET OVERVIEW

 

3.1. Market definition and scope

3.2. Key findings

 

3.2.1. Top investment pockets

 

3.3. Top Player Positioning, 2017

3.4. Porters five forces analysis

3.5. Market dynamics

 

3.5.1. Drivers

 

3.5.1.1. Lack of proper sanitation and consumption of contaminated food

3.5.1.2. Rise in awareness about cholera preventive care

3.5.1.3. Development of novel approaches for new cholera vaccine

 

3.5.2. Restraints

 

3.5.2.1. Risk of adverse effects

3.5.2.2. The time taken for the regulatory approval

 

3.5.3. Opportunities

 

3.5.3.1. High growth opportunities in untapped markets

 

CHAPTER 4: CHOLERA VACCINE MARKET, BY PRODUCT

 

4.1. Overview

 

4.1.1. Market size and forecast

 

4.2. Dukoral

 

4.2.1. Key market trends and growth opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market analysis, by country

 

4.3. Shanchol

 

4.3.1. Key market trends and growth opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market analysis, by country

 

4.4. Vaxchora

 

4.4.1. Key market trends and growth opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market analysis, by country

 

4.5. Euvichol & Euvichol-Plus

 

4.5.1. Key market trends and growth opportunities

4.5.2. Market size and forecast, by region

4.5.3. Market analysis, by country

 

4.6. Others

 

4.6.1. Key market trends and growth opportunities

4.6.2. Market size and forecast, by region

4.6.3. Market analysis, by country

 

CHAPTER 5: CHOLERA VACCINE MARKET, BY END USER

 

5.1. Overview

 

5.1.1. Market size and forecast

 

5.2. Hospitals & Clinics

 

5.2.1. Market size and forecast, by region

5.2.2. Market analysis, by country

 

5.3. Research & Academic Laboratories

 

5.3.1. Market size and forecast, by region

5.3.2. Market analysis, by country

 

5.4. Others

 

5.4.1. Market size and forecast, by region

5.4.2. Market analysis, by country

 

CHAPTER 6: CHOLERA VACCINE MARKET, BY REGION

 

6.1. Overview

 

6.1.1. Market size and forecast

 

6.2. North America

 

6.2.1. Key market trends and opportunities

6.2.2. North America cholera vaccine market, by country

 

6.2.2.1. U.S. cholera vaccine market by product

6.2.2.2. U.S. cholera vaccine market by end user

6.2.2.3. Canada cholera vaccine market by product

6.2.2.4. Canada cholera vaccine market by end user

6.2.2.5. Mexico cholera vaccine market by product

6.2.2.6. Mexico cholera vaccine market by end user

 

6.2.3. North America cholera vaccine market, by product

6.2.4. North America cholera vaccine market, by end user

 

6.3. Europe

 

6.3.1. Key market trends and opportunities

6.3.2. Europe cholera vaccine market, by country

 

6.3.2.1. Germany cholera vaccine market by product

6.3.2.2. Germany cholera vaccine market by end user

6.3.2.3. France cholera vaccine market by product

6.3.2.4. France cholera vaccine market by end user

6.3.2.5. UK cholera vaccine market by product

6.3.2.6. UK cholera vaccine market by end user

6.3.2.7. Italy cholera vaccine market by product

6.3.2.8. Italy cholera vaccine market by end user

6.3.2.9. Sweden cholera vaccine market by product

6.3.2.10. Sweden cholera vaccine market by end user

6.3.2.11. Rest of Europe cholera vaccine market by product

6.3.2.12. Rest of Europe cholera vaccine market by end user

 

6.3.3. Europe cholera vaccine market, by product

6.3.4. Europe cholera vaccine market, by end user

 

6.4. Asia-Pacific

 

6.4.1. Key market trends and opportunities

6.4.2. Asia-Pacific cholera vaccine market, by country

 

6.4.2.1. Australia cholera vaccine market by product

6.4.2.2. Australia cholera vaccine market by end user

6.4.2.3. Japan cholera vaccine market by product

6.4.2.4. Japan cholera vaccine market by end user

6.4.2.5. India cholera vaccine market by product

6.4.2.6. India cholera vaccine market by end user

6.4.2.7. Vietnam cholera vaccine market by product

6.4.2.8. Vietnam cholera vaccine market by end user

6.4.2.9. Rest of Asia-Pacific cholera vaccine market by product

6.4.2.10. Rest of Asia-Pacific cholera vaccine market by end user

 

6.4.3. Asia-Pacific cholera vaccine market, by product

6.4.4. Asia-Pacific cholera vaccine market, by end user

 

6.5. LAMEA

 

6.5.1. Key market trends and opportunities

6.5.2. LAMEA cholera vaccine market, by country

 

6.5.2.1. Nigeria cholera vaccine market by product

6.5.2.2. Nigeria cholera vaccine market by end user

6.5.2.3. Malawi cholera vaccine market by product

6.5.2.4. Malawi cholera vaccine market by end user

6.5.2.5. Zambia cholera vaccine market by product

6.5.2.6. Zambia cholera vaccine market by end user

6.5.2.7. Rest of LAMEA cholera vaccine market by product

6.5.2.8. Rest of LAMEA cholera vaccine market by end user

 

6.5.3. LAMEA cholera vaccine market, by product

6.5.4. LAMEA cholera vaccine market, by end user

 

CHAPTER 7: COMPANY PROFILES

 

7.1. Astellas Pharma, Inc.

 

7.1.1. Company overview

7.1.2. Company snapshot

7.1.3. Business performance

 

7.2. Celldex Therapeutics, Inc.

 

7.2.1. Company overview

7.2.2. Company snapshot

7.2.3. Business performance

7.2.4. Key strategic moves and developments

 

7.3. Emergent BioSolutions, Inc. (PaxVax, Inc.)

 

7.3.1. Company overview

7.3.2. Company snapshot

7.3.3. Operating business segments

7.3.4. Business performance

 

7.4. Eubiologics Co., Ltd.

 

7.4.1. Company overview

7.4.2. Company snapshot

 

7.5. Johnson & Johnson (Crucell)

 

7.5.1. Company overview

7.5.2. Company snapshot

7.5.3. Operating business segments

7.5.4. Business performance

 

7.6. Sanofi (Shantha Biotechnics Private Limited)

 

7.6.1. Company overview

7.6.2. Company snapshot

7.6.3. Operating business segments

7.6.4. Business performance


List Of Figure

LIST OF FIGURES

 

FIGURE 01. CHOLERA VACCINE MARKET SEGMENTATION

FIGURE 02. TOP INVESTMENT POCKETS IN THE GLOBAL CHOLERA VACCINE MARKET

FIGURE 03. GLOBAL POWERED SURGICAL INSTRUMENT TOP PLAYER POSITIONING, 2017

FIGURE 04. MODERATE BARGAINING POWER OF BUYERS

FIGURE 05. HIGH BARGAINING POWER OF SUPPLIERS

FIGURE 06. LOW THREAT OF NEW ENTRANTS

FIGURE 07. MODERATE THREAT OF SUBSTITUTION

FIGURE 08. HIGH COMPETITIVE RIVALRY

FIGURE 09. DRIVERS, RESTRAINTS, AND OPPORTUNITIES: GLOBAL CHOLERA VACCINE MARKET

FIGURE 10. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR DUKORAL, BY COUNTRY, 2017 & 2025 (USD MILLION)

FIGURE 11. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR SHANCHOL, BY COUNTRY, 2017 & 2025 (USD MILLION)

FIGURE 12. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR VAXCHORA, BY COUNTRY, 2017 & 2025 (USD MILLION)

FIGURE 13. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR EUVICHOL AND EUVICHOL-PLUS, BY COUNTRY, 2017 & 2025 (USD MILLION)

FIGURE 14. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR OTHER PRODUCTES, BY COUNTRY, 2017 & 2025 (USD MILLION)

FIGURE 15. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2017 & 2025 (USD MILLION)

FIGURE 16. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY COUNTRY, 2017 & 2025 (USD MILLION)

FIGURE 17. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR OTHER END USERS, BY COUNTRY, 2017 & 2025 (USD MILLION)

FIGURE 18. ASTELLAS PHARMA: NET SALES, 20162018 (USD MILLION)

FIGURE 19. ASTELLAS PHARMA: REVENUE SHARE BY PRODUCT SEGMENT, 2018 (%)

FIGURE 20. ASTELLAS PHARMA: REVENUE SHARE BY GEOGRAPHY, 2018 (%)

FIGURE 21. CELLDEX: NET SALES, 20152017 (USD MILLION)

FIGURE 22. EMERGENT BIOSOLUTIONS: NET SALES, 20152017 (USD MILLION)

FIGURE 23. EMERGENT BIOSOLUTIONS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 24. J&J: NET SALES, 20152017 (USD MILLION)

FIGURE 25. J&J: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 26. J&J: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 27. SANOFI: NET SALES, 20152017 (USD MILLION)

FIGURE 28. SANOFI: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 29. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2017 (%)


List Of Table

LIST OF TABLES

 

TABLE 01. GLOBAL CHOLERA VACCINE MARKET, BY PRODUCT, 20172025 (USD MILLION)

TABLE 02. CHOLERA VACCINE MARKET FOR DUKORAL, BY REGION, 20172025 (USD MILLION)

TABLE 03. CHOLERA VACCINE MARKET FOR SHANCHOL, BY REGION, 20172025 (USD MILLION)

TABLE 04. CHOLERA VACCINE MARKET FOR VAXCHORA, BY REGION, 20172025 (USD MILLION)

TABLE 05. CHOLERA VACCINE MARKET FOR EUVICHOL AND EUVICHOL-PLUS BY REGION, 20172025 (USD MILLION)

TABLE 06. CHOLERA VACCINE MARKET FOR OTHER PRODUCTES BY REGION, 20172025 (USD MILLION)

TABLE 07. GLOBAL CHOLERA VACCINE MARKET, BY END USER, 20172025 (USD MILLION)

TABLE 08. CHOLERA VACCINE MARKET FOR HOSPITALS & CLINICS, BY REGION, 20172025 (USD MILLION)

TABLE 09. CHOLERA VACCINE MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY REGION, 20172025 (USD MILLION)

TABLE 10. CHOLERA VACCINE MARKET FOR OTHER END USERS, BY REGION, 20172025 (USD MILLION)

TABLE 11. GLOBAL CHOLERA VACCINE MARKET REVENUE, BY REGION, 20172025 (USD MILLION)

TABLE 12. NORTH AMERICA CHOLERA VACCINE MARKET, BY COUNTRY, 2017-2025 (USD MILLION)

TABLE 13. U.S. CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 14. U.S. CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 15. CANADA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 16. CANADA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 17. MEXICO CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 18. MEXICO CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 19. NORTH AMERICA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 20. NORTH AMERICA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 21. EUROPE CHOLERA VACCINE MARKET, BY COUNTRY, 2017-2025 (USD MILLION)

TABLE 22. GERMANY CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 23. GERMANY CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 24. FRANCE CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 25. FRANCE CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 26. UK CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 27. UK CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 28. ITALY CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 29. ITALY CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 30. SWEDEN CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 31. SWEDEN CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 32. REST OF EUROPE CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 33. REST OF EUROPE CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 34. EUROPE CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 35. EUROPE CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 36. ASIA-PACIFIC CHOLERA VACCINE MARKET, BY COUNTRY, 2017-2025 (USD MILLION)

TABLE 37. AUSTRALIA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 38. AUSTRALIA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 39. JAPAN CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 40. JAPAN CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 41. INDIA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 42. INDIA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 43. VIETNAM CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 44. VIETNAM CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 45. REST OF ASIA-PACIFIC CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 46. REST OF ASIA-PACIFIC CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 47. ASIA-PACIFIC CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 48. ASIA-PACIFIC CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 49. LAMEA CHOLERA VACCINE MARKET, BY COUNTRY, 2017-2025 (USD MILLION)

TABLE 50. NIGERIA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 51. NIGERIA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 52. MALAWI CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 53. MALAWI CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 54. ZAMBIA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 55. ZAMBIA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 56. REST OF LAMEA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 57. REST OF LAMEA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 58. LAMEA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 (USD MILLION)

TABLE 59. LAMEA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 (USD MILLION)

TABLE 60. ASTELLAS PHARMA: COMPANY SNAPSHOT

TABLE 61. CELLDEX: COMPANY SNAPSHOT

TABLE 62. EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT

TABLE 63. EMERGENT BIOSOLUTIONS: OPERATING SEGMENTS

TABLE 64. EUBIOLOGICS: COMPANY SNAPSHOT

TABLE 65. J&J: COMPANY SNAPSHOT

TABLE 66. J&J: OPERATING SEGMENTS

TABLE 67. SANOFI: COMPANY SNAPSHOT

TABLE 68. SANOFI: OPERATING SEGMENTS

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS